NCT05349045招募中不适用
Containing Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Anti-tumor Treatment of Chinese Patients With Unresectable Locally Advanced / Recurrent or Metastatic Esophageal Cancer: a Real World Study
The First Affiliated Hospital of Zhengzhou University1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2022年5月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Esophageal cancer confirmed by histopathology or cytology
- •Unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy
- •Esophageal cancer patients who benefit from the use of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor evaluated by the researchers
- •Patients who sign informed consent and voluntarily join the study
排除标准
- •Patients who are recommended not using an anti-PD-1/PD-L1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study
- •Patients who are undergoing treatment regimen of blind trial
研究组 & 干预措施
an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor group
干预措施: an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor (Drug)
结局指标
主要结局
PFS
时间窗: From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Progression Free Survival
次要结局
- OS(From date of admission until the date of death from any cause, assessed up to 24 months)
研究者
Feng Wang
Chief physician
The First Affiliated Hospital of Zhengzhou University
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCHepatocellular CarcinomaNCT04639284Shanghai Zhongshan Hospital200
招募中
2 期
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCUnresectable Hepatocellular CarcinomaNCT06360042Peking University Cancer Hospital & Institute111
尚未招募
不适用
Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver CancerCarcinoma, HepatocellularNCT05383066Peking University First Hospital490
已完成
2 期
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 InhibitorNSCLCNCT04691388Zhejiang Cancer Hospital29
已完成
1 期
Trial Of Pembrolizumab And NintedanibPatients With Any Advanced Solid TumorsNCT02856425Gustave Roussy, Cancer Campus, Grand Paris196